• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardiovascular disease and chronic kidney disease.

作者信息

Gargiulo Richard, Suhail Faten, Lerma Edgar V

出版信息

Dis Mon. 2015 Sep;61(9):403-13. doi: 10.1016/j.disamonth.2015.07.005. Epub 2015 Aug 29.

DOI:10.1016/j.disamonth.2015.07.005
PMID:26328516
Abstract
摘要

相似文献

1
Cardiovascular disease and chronic kidney disease.心血管疾病和慢性肾病。
Dis Mon. 2015 Sep;61(9):403-13. doi: 10.1016/j.disamonth.2015.07.005. Epub 2015 Aug 29.
2
[Chronic kidney disease--update 2014].[慢性肾脏病——2014年更新]
Dtsch Med Wochenschr. 2014 Feb;139(6):261-3. doi: 10.1055/s-0033-1360018. Epub 2014 Jan 28.
3
[Cardiovascular disease in patients with 4 and 5 stage chronic kidney disease. Patient in chronic dialysis].[4期和5期慢性肾病患者的心血管疾病。慢性透析患者]
Nefrologia. 2004;24 Suppl(6):142-60, 187-235.
4
Epicardial adipose tissue: A cardiovascular risk marker to evaluate in chronic kidney disease.心外膜脂肪组织：慢性肾脏病中评估心血管风险的标志物。
Clin Investig Arterioscler. 2020 May-Jun;32(3):129-134. doi: 10.1016/j.arteri.2019.10.006. Epub 2020 Jan 21.
5
Kidney disease and cardiovascular risk.肾脏疾病与心血管风险。
Annu Rev Med. 2007;58:123-39. doi: 10.1146/annurev.med.58.071105.111123.
6
It's about time: extending our understanding of cardiovascular risk from chronic kidney disease.是时候了：拓展我们对慢性肾脏病心血管风险的认识。
J Am Soc Nephrol. 2009 Dec;20(12):2486-7. doi: 10.1681/ASN.2009101045. Epub 2009 Nov 5.
7
Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response.慢性肾脏病中的内皮功能障碍：终末器官损伤易感性及治疗反应的决定因素
J Nephrol. 2006 May-Jun;19(3):246-58.
8
[Chronic renal insufficiency and cardiovascular disease].[慢性肾功能不全与心血管疾病]
Ann Cardiol Angeiol (Paris). 2009 Feb;58(1):40-52. doi: 10.1016/j.ancard.2008.07.010. Epub 2008 Aug 19.
9
Author's reply: To PMID 23618914.作者回复：致PMID 23618914。
J Cardiol. 2014 Sep;64(3):242. doi: 10.1016/j.jjcc.2014.01.008. Epub 2014 Apr 13.
10
What happens to the heart in chronic kidney disease?慢性肾病时心脏会发生什么变化？
J R Coll Physicians Edinb. 2017 Mar;47(1):76-82. doi: 10.4997/JRCPE.2017.117.

引用本文的文献

1
Causal relationship between cardiovascular diseases and vestibular dysfunction: A 2-sample Mendelian randomization study.心血管疾病与前庭功能障碍之间的因果关系：一项双样本孟德尔随机化研究。
Medicine (Baltimore). 2025 Jul 18;104(29):e43091. doi: 10.1097/MD.0000000000043091.
2
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.用于非透析慢性肾脏病患者的HMG辅酶A还原酶抑制剂（他汀类药物）
Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
3
The Ratio of Estimated Glomerular Filtration Rate Based on Cystatin C and Creatinine Reflecting Cardiovascular Risk in Diabetic Patients.
基于胱抑素 C 和肌酐的估算肾小球滤过率比值反映糖尿病患者的心血管风险。
Diabetes Metab J. 2023 May;47(3):415-425. doi: 10.4093/dmj.2022.0177. Epub 2023 Mar 6.
4
The roles of sodium and volume overload on hypertension in chronic kidney disease.钠和容量超负荷在慢性肾脏病高血压中的作用。
Kidney Res Clin Pract. 2021 Dec;40(4):542-554. doi: 10.23876/j.krcp.21.800. Epub 2021 Nov 17.
5
The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu.成纤维细胞生长因子 23 对正常和尿毒症环境中心肌细胞的影响的复杂性。
Cells. 2021 May 20;10(5):1266. doi: 10.3390/cells10051266.
6
The relationship of indoxyl sulfate and p-cresyl sulfate with target cardiovascular proteins in hemodialysis patients.透析患者中硫酸吲哚酚和对甲酚硫酸与靶心血管蛋白的关系。
Sci Rep. 2021 Feb 15;11(1):3786. doi: 10.1038/s41598-021-83383-x.
7
Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function.直接口服抗凝剂试验中在整个肾功能谱中的血栓栓塞和出血结局。
Clin Pharmacol Ther. 2021 Jun;109(6):1593-1605. doi: 10.1002/cpt.2131. Epub 2021 Jan 19.
8
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?过氧化物酶体增殖物激活受体α 调节剂（SPPARMα）：降低慢性肾脏病患者残余心血管风险的新机遇？
Curr Atheroscler Rep. 2020 Jul 15;22(8):43. doi: 10.1007/s11883-020-00860-w.
9
Targeting Vascular Calcification in Chronic Kidney Disease.针对慢性肾脏病中的血管钙化
JACC Basic Transl Sci. 2020 Apr 27;5(4):398-412. doi: 10.1016/j.jacbts.2020.02.002. eCollection 2020 Apr.
10
Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease.老年晚期慢性肾脏病患者的药物负担和不适当处方风险。
BMC Geriatr. 2020 Mar 4;20(1):87. doi: 10.1186/s12877-020-1485-4.